Noteworthily, the exploratory analysis between PFS and baseline characteristic subgroups in our study indicated that elderly patients with advanced NSCLC might benefit from PD-1 inhibitor monotherapy uniformly regardless of the majority baseline characteristic subgroups, which highlighted that the effectiveness of PD-1 blockades was stable and balanced across different baseline characteristic subgroups [34]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.